Tirzepatide
Tirzepatide is the step up from a single-hormone GLP-1 drug, hitting two gut-hormone receptors instead of one for a stronger pull on appetite and blood sugar both. It works the same basic idea as semaglutide, mimicking hormones released after eating, but the second receptor typically means sharper appetite shutoff and more weight lost. People move to it from semaglutide when the loss stalls, or start here directly for diabetes or weight management. Like its sibling, it is a once-weekly shot, titrated up slowly over months.
What it does
Blood sugar control
If a single-receptor GLP-1 controlled your blood sugar only partway, tirzepatide is the next lever available before insulin. It works two gut-hormone receptors instead of one, GIP alongside GLP-1, and in head-to-head comparisons that combination brought glucose down further than semaglutide alone. Dosing is a once-weekly injection, stepped up over about four months from a low starting dose to whatever level keeps numbers steady. Nausea and other stomach symptoms hit hardest during that climb, same as with any drug in this class.
Sources: Mounjaro (tirzepatide) FDA
More weight lost
People often land on tirzepatide because the numbers beat semaglutide's in the comparisons that have been run, the extra GIP receptor doing work the single-hormone drugs do not. As Zepbound it is used for chronic weight management, the weekly dose built up over about four months to a maintenance level between 10 and 15 mg. In head-to-head and cross-trial comparisons, that dual action has produced more weight loss than GLP-1-only drugs like semaglutide. It carries the same boxed warning for thyroid tumors, seen in rodents, as every drug in this class.
Sources: Zepbound (tirzepatide) FDA, Jastreboff AM, et al., 2022, Search-aggregated FDA label, 2025
Sleep apnea relief
If obesity is part of why you stopped sleeping through the night, tirzepatide is the only drug in this class actually cleared for that. As Zepbound, it became the first medication ever approved for moderate to severe obstructive sleep apnea in adults with obesity, cleared in December 2024 on the strength of a dedicated trial. It runs on the same weekly injection and titration schedule used for weight loss, this time with a second label attached. It also carries a caution about aspiration risk under anesthesia, worth flagging if a procedure is coming up.
Sources: Zepbound (tirzepatide) FDA, Sleep Foundation: Zepbound, Eli Lilly investor, Search-aggregated FDA label, 2025, Eli Lilly medical
Dosing
Community reportedCommunity titration (peptidedosages.com)2.5 mg to 12.5-15 mg, weekly
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Weeks 1-4 | 2.5 mg | weekly | Starting dose1 |
| Weeks 5-8 | 5 mg | weekly | |
| Weeks 9-12 | 7.5 mg | weekly | |
| Weeks 13-16 | 10 mg | weekly | |
| Week 17+ | 12.5-15 mg | weekly | If tolerated2 |
- Reduces gastrointestinal effects during the initial titration month; not a therapeutic dose on its own.
- This schedule mirrors the FDA label's titration steps; peptidedosages.com frames it as an educational community protocol, not FDA-approved clinical dosing guidance. See Full research for the label dose itself.
Primary structure
No sequence recorded for this compound.
Full research
Evidence tier
Approved drug, human RCT evidence
Tirzepatide is FDA-approved with large phase 3 randomized controlled trial support, for example SURMOUNT-1 for chronic weight management (Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216. PMID 35658024. doi:10.1056/NEJMoa2206038).
Original dosing schedule
The Dosing table above this section now shows a community- or vendor-sourced schedule (peptidedosages.com). The regulatory-label or clinical-trial dosing this entry was originally built on is kept here, unchanged, rather than removed.
Regulatory label
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Weeks 1-4 | 2.5 mg | weekly | Starting dose1 |
| Weeks 5-8 | 5 mg | weekly | |
| Weeks 9-12 | 7.5 mg | weekly | |
| Weeks 13-16 | 10 mg | weekly | |
| Week 17+ | 12.5-15 mg | weekly | If tolerated2 |
- Not a therapeutic dose; reduces gastrointestinal effects during the first month.
- Optional further increase in 2.5 mg steps after at least 4 weeks at the current dose. Adult maximum 15 mg weekly (10 mg weekly under 18, Mounjaro label). Zepbound weight-management maintenance is 5, 10, or 15 mg weekly; its obstructive-sleep-apnea maintenance is 10 or 15 mg weekly.
Identity
| Full name | Tirzepatide, a 39-amino-acid single-molecule synthetic peptide engineered on a GIP peptide backbone, acylated with a C20 fatty diacid moiety. |
|---|---|
| Class | GIP/GLP-1 receptor co-agonist, dual agonism (two receptors) |
| Brand names | Mounjaro, Zepbound |
| Molecular weight | 4813.53 g/mol |
Mechanism of action
Plain language
Tirzepatide activates two different gut-hormone receptors at once (GIP and GLP-1), which together produce stronger appetite suppression and blood-sugar control than hitting either one alone.
Technical
Tirzepatide is a dual GIP/GLP-1 receptor co-agonist. It is a single peptide, not a combination of two drugs, engineered to bind and activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. GIP receptor agonism contributes additional insulinotropic and adipose-tissue effects beyond GLP-1 agonism alone; the combined activation is associated with greater weight loss and glycemic effect in head-to-head and cross-trial comparisons than the GLP-1-monoagonist class. The C20 fatty diacid enables albumin binding and a roughly 5-day half-life supporting once-weekly dosing.
Sources: Mounjaro (tirzepatide) FDA
What it’s used for
Approved
- Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes (Mounjaro).
Sources: Mounjaro (tirzepatide) FDA
- Chronic weight management in adults with obesity, or overweight plus at least one weight-related comorbidity, combined with reduced-calorie diet and increased physical activity (Zepbound).
Sources: Zepbound (tirzepatide) FDA
- Moderate-to-severe obstructive sleep apnea in adults with obesity, approved December 20, 2024, the first drug approved for this indication, based on the SURMOUNT-OSA trial (Zepbound).
Sources: Zepbound (tirzepatide) FDA, Sleep Foundation: Zepbound, Eli Lilly investor
Human trials, not approved for this use
- Tirzepatide reduces alcohol consumption in people with obesity, per observational and early trial data.
Sources: PMC review, semaglutide
Off-label / community use
- Widespread off-label prescribing for weight loss outside the labeled obesity or overweight-plus-comorbidity population.
Sources: Jastreboff AM, et al., 2022
- Polycystic ovary syndrome (PCOS)-related insulin resistance and androgen excess is discussed as an emerging off-label use in commercial and clinic commentary, but no completed phase 3 PCOS trial for tirzepatide was identified; treat as anecdotal or commercial framing, not trial evidence, until a specific trial citation exists.
Sources: Doctronic, commercial clinic
Pharmacokinetics
| Half-life |
Regulatory label approximately 5 days (Mounjaro label); approximately 5-6 days (Zepbound label) Sources: Mounjaro (tirzepatide) FDA, Zepbound (tirzepatide) FDA |
|---|---|
| Time to peak (Tmax) |
Regulatory label median 24 hours, range 8-72 hours post-injection Sources: Mounjaro (tirzepatide) FDA, Zepbound (tirzepatide) FDA |
| Absolute bioavailability (subcutaneous) |
Regulatory label mean 80% Sources: Mounjaro (tirzepatide) FDA, Zepbound (tirzepatide) FDA |
| Route |
Regulatory label subcutaneous injection only (abdomen, thigh, or upper arm; rotate injection sites) Sources: Mounjaro (tirzepatide) FDA, Zepbound (tirzepatide) FDA |
Reconstitution
| Vial strength | 30 mg (commonly advertised compounded/research vial; other vendors sell 10, 20, 40, or 60 mg vials) |
|---|---|
| Diluent | Bacteriostatic water |
| Diluent volume | 3 mL |
| Concentration | 10 mg/mL |
Sources: SeekPeptides tirzepatide reconstitution, Fifty410 FAQ: understanding
Dose calculator
Enter a vial strength, diluent volume, and desired dose to see the resulting concentration, dose volume, and units on a standard U-100 insulin syringe. Nothing entered here is saved, stored, or sent anywhere – the calculation runs only in your browser.
This calculator needs JavaScript. The arithmetic it runs is: concentration = vial strength in mg divided by diluent volume in mL; dose volume in mL = dose in mg divided by concentration; units on a U-100 syringe = dose volume in mL times 100.
Storage and post-reconstitution stability
Unopened storage
Before first use, refrigerate 2-8C (36-46F); do not freeze; may be stored at room temperature up to 86F (30C) for up to 21 days before first use (Mounjaro label language). In-use: Mounjaro, refrigerate after first use and use within 21 days; Zepbound, discard 30 days after first use, after four weekly doses, or 30 cumulative room-temperature days, whichever comes first; once moved to room temperature, do not return to the refrigerator.
Post-reconstitution stability – Vendor claim
approximately 28 days refrigerated at 2-8C. 2-8C, refrigerated
Sources: GLP3 Planner tirzepatide
No citable figure. This is a commercial claim, not an FDA-established figure; no regulatory-grade post-reconstitution stability data exists for the compounded vial form.
Safety
Boxed warning
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO/ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Sources: Mounjaro (tirzepatide) FDA, Zepbound (tirzepatide) FDA
- Known serious hypersensitivity to tirzepatide or any excipient.
Sources: Mounjaro (tirzepatide) FDA, Zepbound (tirzepatide) FDA
Notable risks
- Severe gastrointestinal reactions; acute pancreatitis; acute gallbladder disease (cholelithiasis, biliary colic, cholecystectomy), reported in 0.6% of Mounjaro-treated patients versus 0% placebo in placebo-controlled trials.
Sources: Search-aggregated FDA label, 2025
- Hypoglycemia, risk lowered by reducing concomitant sulfonylurea or insulin dose; acute kidney injury (postmarketing reports, some requiring hemodialysis, mostly in patients with GI-adverse-effect-driven dehydration); hypersensitivity reactions including anaphylaxis and angioedema.
Sources: Search-aggregated FDA label, 2025
- Diabetic retinopathy complications in type 2 diabetes; suicidal behavior and ideation; pulmonary aspiration risk under general anesthesia or deep sedation, attributed to delayed gastric emptying.
Sources: Search-aggregated FDA label, 2025, Eli Lilly medical
- Common adverse effects: nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions; dose-related, most pronounced during titration.
Sources: Mounjaro (tirzepatide) FDA
- Monitoring: watch for pancreatitis and gallbladder symptoms; monitor renal function in patients with significant GI adverse effects; monitor blood glucose closely and adjust concomitant insulin or secretagogue doses when combined; screen for mood changes or suicidal ideation; discuss pre-procedure fasting and anesthesia risk given delayed gastric emptying.
Sources: Search-aggregated FDA label, 2025, Eli Lilly medical
Sources
- Mounjaro (tirzepatide) FDA label, via DailyMed
- Zepbound (tirzepatide) FDA label, via DailyMed
- Sleep Foundation: Zepbound approved to treat obstructive sleep apnea
- Eli Lilly investor release, Zepbound obstructive sleep apnea approval
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 (2022)
- PMC review, semaglutide and tirzepatide effects on alcohol consumption
- Doctronic, commercial clinic commentary on tirzepatide off-label uses
- SeekPeptides tirzepatide reconstitution chart (commercial)
- Fifty410 FAQ: understanding compounded tirzepatide dosing, 20 mg/mL versus 10 mg/mL (commercial)
- GLP3 Planner tirzepatide reconstitution guide (commercial)
- Drugs.com medical answer: how long Zepbound can be left in the fridge
- Search-aggregated FDA label warnings for tirzepatide (2025)
- Eli Lilly medical information page on Mounjaro warnings and precautions
- peptidedosages.com, Tirzepatide 5 mg vial dosage protocol
This is a research and educational reference, not medical advice. Nothing on this site is a recommendation to use any compound.